Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease

Genes and Immunity

Volumn 3, Issue 7, 2002, Pages 400-406

  Vijgen, L ^a   Van Gysel, M ^a   Rector, A ^a   Thoelen, I ^a   Esters, N ^b   Ceelen, T ^a   Vangoidsenhoven, E ^a   Vermeire, S ^b   Rutgeerts, P ^b   Van Ranst, M ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Inflammatory bowel disease; Interleukin 1; Interleukin 1 receptor antagonist; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENTERITIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TANDEM REPEAT; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CARRIER PROTEINS; CHILD; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MINISATELLITE REPEATS; MOLECULAR SEQUENCE DATA; NOD2 SIGNALING ADAPTOR PROTEIN; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS;

EID: 19044372365     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6363888     Document Type: Article

References (38)

1. Binder V. Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998; 16: 351-355.
2. Calkins BM, Mendelhoff AI. The epidemiology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG (eds). Inflammatory Bowel Disease. Williams & Wilkins: Baltimore, 1995, pp. 31-68.
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
4. Papadakis KA, Targan SR. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 283-296.
5. Orchard TR, Satsangi J, Van Heel D, Jewell DP. Genetics of inflammatory bowel disease: a reappraisal. Scand J Immunol 2000; 51: 10-17.
6. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995; 24: 475-507.
7. Ardizzone S, Bollani S, Manzionna G, Bianchi Porro G. Inflammatory bowel disease approaching the 3rd millennium: pathogenesis and therapeutic implications? Eur J Gastroenterol Hepatol 1999; 11: 27-32.
8. Satsangi J, Parkes M, Jewell DP, Bell JI. Genetics of inflammatory bowel disease. Clin Sci 1998; 94: 473-478.
9. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
10. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
11. Lesage S, Zouali H, Cézard JP et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-857.
12. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 1445-1451.
13. Tountas NA, Casini-Raggi V, Yang H et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999; 117: 806-813.
14. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis 2000; 59 (Suppl): i60-i64.
15. Lennard AC. Interleukin-1 receptor antagonist. Crit Rev Immunol 1995; 15: 77-105.
16. Tarlow JK, Blakemore AI, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-404.
17. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1380-1385.
18. Clay FE, Cork MJ, Tarlow JK et al. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosis. Hum Genet 1994; 94: 407-410.
19. Tarlow JK, Cork MJ, Clay FE et al. Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol 1997; 136: 147-148.
20. Bioque G, Bouma G, Crusius JB et al. Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenter Hepatol 1996; 8: 105-110.
21. Mansfield JC, Holden H, Tarlow JK et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637-642.
22. Heresbach D, Alizadeh M, Dabadie A et al. Significance of the interleukin-1 beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 1164-1169.
23. Carter MJ, di Giovine FS, Jones S et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001; 48: 461-467.
24. Louis E, Satsangi J, Roussomoustakaki M et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996; 39: 705-710.
25. Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-1853.
26. Craggs A, West S, Curtis A et al. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand J Gastroenterol 2001; 36: 1173-1178.
27. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998; 47: 195-198.
28. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 1992; 13: 654-657.
29. Patterson D, Jones C, Hart I et al. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics 1993; 15: 173-176.
30. Nemetz A, Nosti-Escanilla MP, Molnar T et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999; 49: 527-531.
31. Pillay V, Gaillard MC, Halkas A, Song E, Dewar JB. Differences in the genotypes and plasma concentrations of the interleukin-1 receptor antagonist in black and white South African asthmatics and control subjects. Cytokine 2000; 12: 819-821.
32. Tanigawara Y, Kita T, Hirono M, Sakaeda T, Komada F, Okumura K. Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood. Ther Drug Monit 2001; 23: 341-346.
33. Bouma G, Oudkerk Pool M, Crusius JB et al. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clin Exp Immunol 1997; 109: 175-179.
34. Rector A, Lemey P, Laffut W et al. Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease. Genes Immun 2001; 2: 323-328.
35. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170 (Suppl): 2-6; discussion 16-19.
36. World Medical Association. World Medical Association's Declaration of Helsinki 1964. World Medical Association 1996, Fernay-Voltaire.
37. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
38. Lench N, Stainer P, Williamson R. Simple non-invasive method to obtain DNA for gene analysis. Lancet 1988; 1: 1356-1358.